U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H26ClN3.2H3O4P
Molecular Weight 515.863
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLOROQUINE PHOSPHATE

SMILES

OP(O)(O)=O.OP(O)(O)=O.CCN(CC)CCCC(C)NC1=CC=NC2=C1C=CC(Cl)=C2

InChI

InChIKey=QKICWELGRMTQCR-UHFFFAOYSA-N
InChI=1S/C18H26ClN3.2H3O4P/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18;2*1-5(2,3)4/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21);2*(H3,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H26ClN3
Molecular Weight 319.872
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Chloroquine (brand name Aralen) is indicated for the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum. The drug is also indicated for the treatment of extraintestinal amebiasis. In addition, chloroquine is in clinical trials as an investigational antiretroviral in humans with HIV-1/AIDS and as a potential antiviral agent against chikungunya fever. The mechanism of plasmodicidal action of chloroquine is not completely certain. However, is existed theory, that like other quinoline derivatives, it is thought to inhibit heme polymerase activity. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a non-toxic molecule. Chloroquine enters the red blood cell, inhabiting parasite cell, and digestive vacuole by simple diffusion. Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form what is known as the FP-Chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available.

Originator

Curator's Comment: # Hans Andersag and coworkers at the Bayer laboratories

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ARALEN

Approved Use

ARALEN is indicated for the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum. The drug is also indicated for the treatment of extraintestinal amebiasis. ARALEN does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. It is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. In patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of P. falciparum.

Launch Date

1949
Curative
ARALEN

Approved Use

ARALEN is indicated for the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum. The drug is also indicated for the treatment of extraintestinal amebiasis. ARALEN does not prevent relapses in patients with vivax or malariae malaria because it is not effective against exoerythrocytic forms of the parasite, nor will it prevent vivax or malariae infection when administered as a prophylactic. It is highly effective as a suppressive agent in patients with vivax or malariae malaria, in terminating acute attacks, and significantly lengthening the interval between treatment and relapse. In patients with falciparum malaria it abolishes the acute attack and effects complete cure of the infection, unless due to a resistant strain of P. falciparum.

Launch Date

1949
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
700 ng/mL
5 mg/kg 1 times / day multiple, oral
dose: 5 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLOROQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
134087 ng × h/mL
5 mg/kg 1 times / day multiple, oral
dose: 5 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLOROQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
209 h
5 mg/kg 1 times / day multiple, oral
dose: 5 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLOROQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
45%
5 mg/kg 1 times / day multiple, oral
dose: 5 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLOROQUINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 g single, oral
Overdose
Dose: 3 g
Route: oral
Route: single
Dose: 3 g
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Other AEs: Cardiac arrest...
Other AEs:
Cardiac arrest
Sources:
600 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
pregnant, 20.7 years
n = 300
Health Status: pregnant
Condition: malaria
Age Group: 20.7 years
Sex: F
Population Size: 300
Sources:
Other AEs: Dizziness, Vomiting...
Other AEs:
Dizziness (19%)
Vomiting (17%)
Palpitations (5%)
Headache (6%)
Nausea (5%)
Abdominal pain (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Cardiac arrest
3 g single, oral
Overdose
Dose: 3 g
Route: oral
Route: single
Dose: 3 g
Sources:
unknown, 14 years
n = 1
Health Status: unknown
Age Group: 14 years
Sex: F
Population Size: 1
Sources:
Vomiting 17%
600 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
pregnant, 20.7 years
n = 300
Health Status: pregnant
Condition: malaria
Age Group: 20.7 years
Sex: F
Population Size: 300
Sources:
Dizziness 19%
600 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
pregnant, 20.7 years
n = 300
Health Status: pregnant
Condition: malaria
Age Group: 20.7 years
Sex: F
Population Size: 300
Sources:
Abdominal pain 2%
600 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
pregnant, 20.7 years
n = 300
Health Status: pregnant
Condition: malaria
Age Group: 20.7 years
Sex: F
Population Size: 300
Sources:
Nausea 5%
600 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
pregnant, 20.7 years
n = 300
Health Status: pregnant
Condition: malaria
Age Group: 20.7 years
Sex: F
Population Size: 300
Sources:
Palpitations 5%
600 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
pregnant, 20.7 years
n = 300
Health Status: pregnant
Condition: malaria
Age Group: 20.7 years
Sex: F
Population Size: 300
Sources:
Headache 6%
600 mg 2 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
pregnant, 20.7 years
n = 300
Health Status: pregnant
Condition: malaria
Age Group: 20.7 years
Sex: F
Population Size: 300
Sources:
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no (co-administration study)
Comment: chloroquine did not affect the activities of CYP1A2, CYP2C19, CYP2E1, CYP3A4
no
no (co-administration study)
Comment: chloroquine did not affect the activities of CYP1A2, CYP2C19, CYP2E1, CYP3A4
no
no (co-administration study)
Comment: chloroquine did not affect the activities of CYP1A2, CYP2C19, CYP2E1, CYP3A4
no
no (co-administration study)
Comment: chloroquine did not affect the activities of CYP1A2, CYP2C19, CYP2E1, CYP3A4
yes [IC50 1096 uM]
yes [IC50 2.5 uM]
yes [Ki 12 uM]
weak (co-administration study)
Comment: selective inhibiton; Chloroquine produced a reduction in the metabolism of debrisoquine as evaluated by the debrisoquine recovery ratio, a measure of CYP2D6 activity. This reduction was progressive from the first to the seventh dose. This decrease in metabolism was modest (about 7% after the first dose and about 18% after seven doses) but statistically significant
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes (co-administration study)
Comment: Concomitant administration of a single dose of chloroquine and cimetidine daily starting 4 days prior to chloroquine, resulted in a 50% increase in chloroquine half-life, associated with a 50% decrease in its clearance.Since the AUC of desethylchloroquine decreased by 47%, cimetidine probably decreased chloroquine clearance by inhibiting its hepatic desethylation.
yes
yes (co-administration study)
Comment: Concomitant administration of a single dose of chloroquine and cimetidine daily starting 4 days prior to chloroquine, resulted in a 50% increase in chloroquine half-life, associated with a 50% decrease in its clearance.Since the AUC of desethylchloroquine decreased by 47%, cimetidine probably decreased chloroquine clearance by inhibiting its hepatic desethylation.
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
A Comparative Study of Hymenolepicides in Hymenolepis Mana Infestation of Rats.
1962 Jul
Drug-induced haemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Central Asia.
1990
Inhibition of human immunodeficiency virus infectivity by chloroquine.
1990 Apr
Amrinone for refractory cardiogenic shock following chloroquine poisoning.
1991
Persisting chloroquine-induced myasthenia?
1991
Occurrence of chloroquine-induced psychotic manifestations in children with malaria.
1992
Seizures associated with chloroquine therapy.
1992 Aug
Chloroquine related complete heart block with blindness: case report.
1992 Jan
Involvement of GABAergic mechanisms in chloroquine-induced seizures in mice.
1992 Mar
Syncope following oral chloroquine administration in a hypertensive patient controlled on amlodipine.
2002 Apr
Cardiac damage from chronic use of chloroquine: a case report and review of the literature.
2002 Jul
High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter.
2002 Jun
The first molecular evidence that autophagy relates rimmed vacuole formation in chloroquine myopathy.
2002 May
Side effects of and compliance with malaria prophylaxis in children.
2002 Nov-Dec
[Chloroquine cardiomyopathy revealed by complete atrio-ventricular block. A case report].
2002 Sep
EGb 761 is a neuroprotective agent against beta-amyloid toxicity.
2002 Sep
Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine.
2003 Feb 15
Acute neuropharmacologic action of chloroquine on cortical neurons in vitro.
2003 Jan 10
Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.
2003 Nov
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.
2003 Sep
[Infectious diseases in 2003].
2004
Heart transplantation in a patient with chloroquine-induced cardiomyopathy.
2004 Feb
The antimalarial potential of 4-quinolinecarbinolamines may be limited due to neurotoxicity and cross-resistance in mefloquine-resistant Plasmodium falciparum strains.
2004 Jul
Reactive oxygen species mediate chloroquine-induced expression of chemokines by human astroglial cells.
2004 Jul
Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract.
2004 Jun 11
The multifocal pattern electroretinogram in chloroquine retinopathy.
2004 Mar-Apr
The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity.
2004 Nov
Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus.
2004 Sep
Chloroquine-induced cardiomyopathy-echocardiographic features.
2005 Apr
Enhanced anticryptococcal activity of chloroquine in phosphatidylserine-containing liposomes in a murine model.
2005 Feb
cAMP has distinct acute and chronic effects on aquaporin-5 in lung epithelial cells.
2005 Feb 4
[Acute hydroxychloroquine poisoning. The danger of rapid or excessive correction of initial hypokalemia].
2005 Jul 23
Ginkgo biloba leaf extract (EGb 761) enhances catalepsy induced by haloperidol and L-nitroarginine in mice.
2005 Nov
Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity.
2005 Nov
Images in cardiovascular medicine. Contrast-enhanced magnetic resonance imaging of a patient with chloroquine-induced cardiomyopathy confirmed by endomyocardial biopsy.
2006 Aug 22
CpG-B oligodeoxynucleotide promotes cell survival via up-regulation of Hsp70 to increase Bcl-xL and to decrease apoptosis-inducing factor translocation.
2006 Dec 15
[Complete auriculoventricular block secondary to cardiac toxicity due to chloroquine].
2006 Feb
[Cytochrome P-450 and the response to antimalarial drugs].
2006 Jan
Plasmodium berghei: development of an irreversible experimental malaria model in Wistar rats.
2006 Jul
Mefloquine toxicity presenting with polyneuropathy - a report of two cases in India.
2006 Jun
Frequency of high-risk use of QT-prolonging medications.
2006 Jun
Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.
2006 Mar
Tetrahydrocurcumin: effect on chloroquine-mediated oxidative damage in rat kidney.
2006 Nov
Expression of autophagy-associated genes in skeletal muscle: an experimental model of chloroquine-induced myopathy.
2007
Cardiomyopathy related to antimalarial therapy with illustrative case report.
2007
[Complete auriculoventricular block during chloroquine treatment].
2007 Feb
Effect of chloroquine on gene expression of Plasmodium yoelii nigeriensis during its sporogonic development in the mosquito vector.
2007 Jul 2
Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases.
2007 May
Effects of CpG-B ODN on the protein expression profile of swine PBMC.
2007 Nov-Dec
A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru.
2007 Oct 31
Patents

Sample Use Guides

The dosage of chloroquine phosphate is often expressed in terms of equivalent chloroquine base. Each 500 mg tablet of ARALEN (chloroquine phosphate) contains the equivalent of 300 mg chloroquine base. In infants and children the dosage is preferably calculated by body weight. Malaria: Suppression—Adult Dose: 500 mg (= 300 mg base) on exactly the same day of each week. Pediatric Dose: The weekly suppressive dosage is 5 mg calculated as base, per kg of body weight, but should not exceed the adult dose regardless of weight. If circumstances permit, suppressive therapy should begin two weeks prior to exposure. However, failing this in adults, an initial double (loading) dose of 1 g (= 600 mg base), or in children 10 mg base/kg may be taken in two divided doses, six hours apart. The suppressive therapy should be continued for eight weeks after leaving the endemic area. For Treatment of Acute Attack. Adults: An initial dose of 1 g (=600 mg base) followed by an additional 500 mg (= 300 mg base) after six to eight hours and a single dose of 500 mg (= 300 mg base) on each of two consecutive days. This represents a total dose of 2.5 g chloroquine phosphate or 1.5 g base in three days. The dosage for adults of low body weight and for infants and children should be determined as follows: First dose: 10 mg base per kg (but not exceeding a single dose of 600 mg base) Second dose: (6 hours after first dose) 5 mg base per kg (but not exceeding a single dose of 300 mg base) Third dose: (24 hours after first dose) 5mg base per kg Fourth dose: (36 hours after first dose) 5 mg base per kg For radical cure of vivax and malariae malaria concomitant therapy with an 8-aminoquinoline compound is necessary. Extraintestinal Amebiasis: Adults, 1 g (600 mg base) daily for two days, followed by 500 mg (300 mg base) daily for at least two to three weeks. Treatment is usually combined with an effective intestinal amebicide.
Route of Administration: Oral
Chloroquine inhibited mouse colon cancer cell line CT26 cells proliferation by concentration- and time-dependent manner. This effect was associated with apoptosis induction and decreased level of phosphorylated p42/44 mitogen-activated protein kinase and phosphorylated Akt. The cytotoxicity of chloroquine on CT26 cells was determined by the MTT assay. Cells were seeded in 96-well plates at the density of 2000/well and cultured for 24 hr, followed by chloroquine treatment (100, 50, 25, 12.5, 6.25, and 3.125 μ mol/L) for 24, 48, and 72 hr, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:29:10 GMT 2023
Edited
by admin
on Fri Dec 15 16:29:10 GMT 2023
Record UNII
6E17K3343P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLOROQUINE PHOSPHATE
EP   GREEN BOOK   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
CHLOROQUINE PHOSPHATE [MART.]
Common Name English
CHLOROQUINE PHOSPHATE [EP MONOGRAPH]
Common Name English
CHLOROQUINE PHOSPHATE [GREEN BOOK]
Common Name English
SN-7618
Code English
1,4-PENTANEDIAMINE, N(SUP 4)-(7-CHLORO-4-QUINOLINYL)-N(SUP 1),N(SUP 1)-DIETHYL-, PHOSPHATE (1:2)
Common Name English
NSC-14050
Code English
CHLOROQUINE DIPHOSPHATE
MI  
Common Name English
RESOCHIN
Brand Name English
CHLOROQUINI PHOSPHAS [WHO-IP LATIN]
Common Name English
ARECHIN
Brand Name English
Chloroquine phosphate [WHO-DD]
Common Name English
MALAQUIN
Brand Name English
CHLOROQUINE PHOSPHATE [WHO-IP]
Common Name English
CHLOROQUINE PHOSPHATE [USP-RS]
Common Name English
7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2).
Common Name English
CHLOROQUINE DIPHOSPHATE [MI]
Common Name English
CHLOROQUINE PHOSPHATE [USP MONOGRAPH]
Common Name English
CHLOROQUINE PHOSPHATE [VANDF]
Common Name English
CHLOROQUINE PHOSPHATE [ORANGE BOOK]
Common Name English
AVLOCLOR
Brand Name English
WR-1522
Code English
Classification Tree Code System Code
NCI_THESAURUS C271
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
CHLOROQUINE PHOSPHATE
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder: odourless or almost odourless.Solubility: Soluble in 4 parts of water; very slightly soluble in ethanol (~750 g/l) TS and ether R.Category: Antimalarial; antiamoebic.Storage: Chloroquine phosphate should be kept in a well-closed container, protected from light.
NCI_THESAURUS
C47445
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
DAILYMED
6E17K3343P
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
EVMPD
SUB01238MIG
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
MESH
C023676
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
RS_ITEM_NUM
1118000
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
DRUG BANK
DBSALT000025
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
FDA UNII
6E17K3343P
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
MERCK INDEX
m3435
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY Merck Index
CAS
50-63-5
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
SMS_ID
100000092628
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID7044681
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
ChEMBL
CHEMBL76
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-055-2
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
PUBCHEM
64927
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
EVMPD
SUB37532
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
NSC
14050
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY
RXCUI
20863
Created by admin on Fri Dec 15 16:29:10 GMT 2023 , Edited by admin on Fri Dec 15 16:29:10 GMT 2023
PRIMARY RxNorm
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY